Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Autoplanning in the setting of stereotactic body radiation therapy for lung cancer.
Phys Med
January 2025
University of Turin, Department of Oncology, Turin, Italy.
Purpose: Automatic planning (AP) has been compared to manual planning (MP) in lung stereotactic body radiation therapy (SBRT) to validate the former and to implement it in clinical practice.
Methods: A new developing Guided Planning System (GPS) engine was used to reoptimize 20 lung SBRT plans with the RayStation™ treatment planning system (TPS). The original manual plans were optimized to deliver 60 Gy in 5 or 8 fractions to the target with constraints on organs at risk (OARs) based on an internal protocol.
"Nanoparticle-based sensitizers in prostate cancer treatment: Enhancing radiotherapy efficacy through innovative nanotechnology: Narrative review".
Appl Radiat Isot
January 2025
Behbahan Faculty of Medical Sciences, Behbahan, Iran. Electronic address:
For men with localized prostate cancer, radiotherapy (RT) remains a common therapeutic option. Although radiotherapy has had significant success, it remains an intractable issue in promoting radiation damage to tumor tissue while reducing adverse effects on healthy tissue. Chemicals or pharmacological substances known as radiosensitizers can increase the killing effect on tumor cells by accelerating DNA damage and indirectly producing free radicals.
View Article and Find Full Text PDFA robust auto-contouring and data augmentation pipeline for adaptive MRI-guided radiotherapy of pancreatic cancer with a limited dataset.
Phys Med Biol
January 2025
Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, London, Surrey, SM2 5PT, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.
This study aims to develop and evaluate a fast and robust deep learningbased auto-segmentation approach for organs at risk in MRI-guided radiotherapy of pancreatic cancer to overcome the problems of time-intensive manual contouring in online adaptive workflows. The research focuses on implementing novel data augmentation techniques to address the challenges posed by limited datasets. Approach: This study was conducted in two phases.
View Article and Find Full Text PDFSafety, Biodistribution, and Radiation Dosimetry of the Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
J Nucl Med
January 2025
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).
View Article and Find Full Text PDFAAPM Task Group Report 274: Fluence rate dosimetry for photodynamic therapy (PDT).
Med Phys
January 2025
Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, NKI-AvL, Amsterdam, Netherlands.
Photodynamic therapy (PDT) is a treatment modality clinically approved for several oncologic indications, including esophageal and endobronchial cancers, precancerous conditions including Barrett's esophagus and actinic keratosis, and benign conditions like age-related macular degeneration. While it is currently clinically underused, PDT is an area of significant research interest. Because PDT relies on the absorption of light energy by intrinsic or administered absorbers, the dosimetric quantity of interest is the absorbed energy per unit mass of tissue, proportional to the fluence rate of light in tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!